Zomanex Overview
- Founded
-
2006
- Status
-
Private
- Latest Deal Type
-
Series A
- Investors
-
1
Zomanex General Information
Description
Operator of a drug formulation development company intended to transform intravenous, injectable and oral therapeutics into novel orally delivered medicines. The company's products help in the conversion of intravenous or injectable xenobiotics into orally deliverable substances, as well as make it easy for hydrophobic compounds to be absorbed in the small intestine, enabling physicians to permit oral dosing of pharmaceutical compounds that have previously been administered intravenously or by injection.
Contact Information
Website
www.zomanex.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Drug Delivery
Primary Office
- Suite 2600 Three Bentall Centre
- Post Office Box 49314, 595 Burrard Street
- Vancouver, British Columbia V7X 1L3
- Canada
+1 (604) 000-0000
Zomanex Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Later Stage VC (Series A) | 12-Oct-2017 | Completed | Generating Revenue |
Zomanex Patents
Zomanex Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2008309010-B2 | Methods and formulations for converting intravenous and injectable drugs into oral dosage forms | Inactive | 28-Sep-2007 | 0000000000 | 0 |
| AU-2008309010-A1 | Methods and formulations for converting intravenous and injectable drugs into oral dosage forms | Active | 28-Sep-2007 | 0000000000 | |
| CA-2701023-C | Methods and formulations for converting intravenous and injectable drugs into oral dosage forms | Active | 28-Sep-2007 | 0000000000 | |
| CA-2701023-A1 | Methods and formulations for converting intravenous and injectable drugs into oral dosage forms | Active | 28-Sep-2007 | 0000000000 | |
| EP-2205219-A1 | Methods and formulations for converting intravenous and injectable drugs into oral dosage forms | Active | 28-Sep-2007 | A61K31/337 |
Zomanex Executive Team (3)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Paul Drohan | Chief Executive Officer | ||
| Curtis Spilburg Ph.D | Chief Scientific Officer | ||
| Doris Schnelle | Director, Business Development |
Zomanex Board Members (1)
| Name | Representing | Role | Since |
|---|---|---|---|
| Peter Craddock | Shoreline Venture Management | Board Member | 000 0000 |
Zomanex Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Shoreline Venture Management | Venture Capital | Minority | 000 0000 | 000000 0 |